EuroPCR 2023

This year Edwards Lifesciences presented the TNT session:

TAVI and patient pathway optimisation – Lifetime management decisions today for challenges of the future!

Watch the recording of the session below.

Topics covered:

  • The results of the BENCHMARK registry and how the learnings can be connected to a successful long-term monitoring, increased quality of life and reduced risks for patients
  • Reflecting on future challenges after TAVI in patients with longer-life expectancy
  • Assessing the feasibility of re-do TAVI to understand what is important in order to find the best treatment strategy


Prof. Thomas Cuisset
Aphm Hospital La Timone of Marseille

Prof. Thomas Modine
CHU de Bordeaux

Dr. Mirvat Alasnag
King Fahd Armed Forces Hospital - Jeddah

Prof. Francesco Saia
University Hospital of Bologna

Gemma McCalmont
James Cook Hospital - Middlesbrough

Dr. Janarthanan Sathananthan
Vancouver General and St Paul’s hospital

Prof. Richard Anderson
Spire Cardiff Hospital

Prof. Giuseppe Tarantini
University Hospital of Padua

Mitral and tricuspid solutions

Discover Edwards SAPIEN 3 Ultra valve

Visit the Edwards Lifesciences SAPIEN 3 valve page to learn more about the Edwards SAPIEN 3 and Edwards SAPIEN 3 Ultra valves.

Explore the valve

Sign up now to receive copies of Edwards Lifesciences recorded event sessions post event, as well as receive event and news informations from Edwards Lifesciences, including:


Featuring the latest cardiology news, clinical trials and real-world evidence in aortic stenosis (AS) management.

Panel discussions

Involving leading cardiologists debating the latest topics in transcatheter aortic valve implantation (TAVI) and AS management.

Conference headlines

Providing insights into the major developments from the latest cardiology events.

Guidelines updates

Highlighting the areas of change within any updated aortic stenosis treatment guidelines.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult where applicable).

PP--EU-6299 v1.0